VivoSim Q2 Loss Narrows to $0.5M; Going-Concern Doubt Persists Despite $8.6M Cash
VIVS is trading near its 52-week low of $0.124 (8.2% above the low).
Summary
VivoSim's fiscal Q2 loss narrowed to $0.5M on a $5.0M FXR314 milestone gain, while first service revenue of $22K came with $56K of cost. Management reaffirmed going-concern doubt with $8.6M of cash.
Key Events · Earnings and Guidance · VIVS
-
Q2 Loss Narrows on Milestone Gain
Net loss was $0.5M for the three months ended September 30, 2026 versus $2.5M a year earlier, driven by a $5.0M gain on the FXR314 milestone payment collected in July 2026.
-
First Service Revenue, Negative Gross Margin
Service revenue of $22K carried $56K of cost of services provided in the quarter; management said initial pilot contracts were heavily discounted.
-
Going-Concern Doubt Reaffirmed
Management concluded substantial doubt exists about the ability to continue as a going concern for at least one year, with $8.6M of cash against $5.7M of operating cash burn in the six months.
-
Viscient Liver Model License Signed
On October 29, 2026 the company took an exclusive license to Viscient's NAMKind Liver Model platform for a $100K upfront fee, $150K tech-transfer fee and tiered royalties of 11%/9%/7%.
Analysis · VIVS · Life Sciences
The quarter's headline is a much smaller loss, but almost all of the improvement is a one-time $5.0M milestone payment on the FXR314 asset sale, not operations. Underneath, the services business just booked its first revenue at $22K against $56K of cost, and management again says substantial doubt exists about continuing as a going concern. With $8.6M of cash and roughly $5.7M burned in six months, another raise is likely, and the stock already trades near $0.13 with a Nasdaq minimum-bid deficiency outstanding.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VIVS was trading at $0.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.12 to $3.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.